Bioenergy booster

Bioenergy booster

14.04.2015 - This year’s Norwegian Bioenergy Innovation Award was awarded to Vincent Eijsink, professor at the Norwegian University of Life Sciences (NMBU). The award, which was presented to the molecular scientist on 17th March during the CenBio Days 2015, recognises innovative thinking, research-based development and commercial potential.

According to the award committee, Vincent was honoured for his endeavours and dedication, which has been crucial to the development of Bioenergy in Norway and has also contributed to optimal utilisation of biomass: “His work has had a great, lasting and decisive positive impact on the biogas sector in Norway,” stated the 2015 Committee.

Vincent has a PhD from Groningen, The Netherlands, in enzyme engineering and has been a professor of Biochemistry at NMBU since 1997. He has developed fast enzyme-based methods to test the biogas production potential of various feedstocks mixtures. He is also at the forefront within production of biogas from seaweed, a field with substantial commercial potential. The related fundamental enzyme work, which was published in Science in 2010, has led to several patent applications.

26.02.2015 When Olivier Brandicourt leaves Bayer Health Care at the end of March, Werner Baumann will take over as the company’s Chairman of the Board of Management.

© Bayer

Baumann has been working for Bayer since he joined the company in 1988. He held leading positions since 2002 and was actively involved in the Schering AG integration into Bayer after its acquisition in 2006.

Baumann will remain a member of the Board of Management of Bayer AG, of which he has been a member since 2010. He will also continue on as Chief Strategy and Portfolio Officer responsible for Corporate Development and Mergers & Acquisitions as well as the Europe region. Before taking over this responsibility, Baumann served as Bayer AG’s Chief Financial Officer.

Brandicourt, meanwhile, will take over as Sanofi’s new CEO.

20.02.2015 After Christopher Vieh­bacher’s unceremonious ousting last year, Sanofi has been on the lookout for a new CEO. Now, pharma veteran Olivier Brandicourt has agreed to fill the position.

© Bayer

Brandicourt had been Chief Executive Officer and Chairman of the Board of Management of German Bayer HealthCare AG since 2013. Before that, he was a member of the executive leadership team of Pfizer Inc. in New York, and where he led Pfizer’s Emerging Markets and Established Products business unit as president and general manager. At Sanofi, he will take over from interim CEO and Chairman Serge Weinberg, who has headed the Paris-based drugmaker since October.

19.02.2015 Pfizer’s Global Innovative Pharmaceutical business UK has a new head: Erik Nordkamp is taking over the position from Jonathan Emms, who switched to the pharma giant’s global business unit.

© Pfizer UK

Nordkamp has been working for Pfizer since 2010. He was head of strategy for Primary Care Europe and Canada, and, for the last year, he has been responsible for the company’s Greece, Cyprus and Malta business.

16.02.2015 Jean-Christophe Tellier has taken over the role of UCB's CEO from Roch Doliveux, who had led the Belgian biopharmaceutical company for the last ten years.


Tellier joined the company in 2011 and was instrumental in establishing the company’s current strategy. Previously, the rheumatologist by trade he held leadership roles at Ipsen and Macrogenics. He spent almost 20 years working at Novartis, most notably as CEO Novartis Pharma France and Belgium. Tellier is also Chairman of UCB’s Executive Committee and member of the Board of Directors.

11.02.2015 Eliot Forster has taken over the lead of British biologics specialist Immunocore Limited. The new CEO succeeds founder James Noble who stood down to become full-time CEO of sister company Adaptimmune.

© Immunocore

Forster is joining from Italian biotech Creabilis, where he also held the role of CEO since 2010. Prior to that, he worked in leading roles at Solace Pharmaceuticals, Pfizer and Glaxosmithkline. Forster is also Chairman of the MedCity project, launched last year to grow a world-leading life sciences cluster in and around London.

03.02.2015 Darrin Disley, Horizon Discovery’s CEO has won the Entrepreneur of the Year award at the Quoted Company Awards 2015 in London.

© Horizon Discovery

The Quoted Company Awards, now in its 11th year, recognises the achievements of quoted companies listed outside of the FTSE 350 and their key directors.

Darrin has overseen a transformational year for the Cambridge-based biotech, which supplies research tools and services to organisations engaged in genomics research and the development of personalised medicines. Within a year, Horizon has transitioned from a private UK life science business to a publicly listed international life science group with facilities located in the UK, Austria and the US. Under Darrin’s leadership, Horizon was listed on AIM market or the London Stock Exchange in March 2014. The company raised £68.6m, almost three times the initial target.

In 2012, he was named Business Leader of the Year at the European Life Science Awards. In addition to his role at Horizon, Darrin is also an active entrepreneur and leader in the life science community, where he invests and provides guidance and mentoring to help develop promising young companies.

29.01.2015 MedDay Pharmaceuticals has appointed Philippe Goupit as an independent Non-Executive Director on its board of directors. Mr Goupit brings his significant business and corporate development experience in the biotech and pharma sector to the Parisian-based company, which focuses on the treatment of nervous system disorders.

© MedDay Pharmaceuticals

Philippe, a pharma VIP has over 30 years’ experience in the industry, and has spent 20 years at Sanofi. Until recently he was Vice President, Corporate Licenses at Sanofi. His experience in business development covers M&A, as former head of the corporate M&A group in Sanofi, and licensing activities. Philippe has also served for some years as the Head of Investor Relations at Sanofi.

“Philippe’s broad experience will be hugely beneficial to MedDay as the Company continues to develop its pipeline of assets which address areas of unmet need in neurological and psychiatric diseases, through brain metabolism. Through his experience Philippe will contribute to MedDay’s corporate and business development strategy.”

27.01.2015 On 1 January, Ulla Ruotsalainen was appointed by the board of the TYY Foundation as Vice President of research activities at Tampere University of Technology (TUT), where she will oversee the development of research activities at the university.

© Hovione

With her vast wealth of experience, Ulla has had a long career working for a research institution, the corporate world, a health care unit and the Academy of Finland. She has also served two terms as the Dean of the Faculty of Computing and Electrical Engineering and sat on the Academy of Finland’s Research Council for Natural Sciences and Engineering.

Ruotsalainen places a high value on international research collaboration that cuts across disciplinary boundaries. “The building blocks of a high-quality research environment are a supportive atmosphere that encourages the exploration of new avenues for research and up-to-date equipment,” she says.

Her appointment as Vice President will run until 31 December 2016.

23.01.2015 Filipe Gaspar has been appointed Vice President of Research and Development at the Portuguese pharmaceutical ingredient manufacturer Hovione.

© Hovione

The chemical engineer has worked at Hovione for the last eleven years, mostly in particle engineering, but most recently in a business development role. Gaspar is co-author and co-inventor of numerous publications, scientific presentations and patents.

“For the last 10 years Filipe has been the driving force behind our Particle Engineering, and if we have four new drugs today on the market it is because he and his team made sure we had the right capabilities, knowhow and ability to deliver,” commented Hovione CEO Guy Villax.

21.01.2015 Fredrik Lindgren is the new CEO and president of Swedish clinical stage drug development company Hansa Medical.

© Hansa Medical

He replaces Emanuel Björne, who has led the company since it was established and takes over the role of Corporate Development Director. Lindgren, who holds a law degree from Lund University, has previously held the position of CEO at Karo Bio and Biolin Scientific. He is chairman and member of the board of Prostalund, Larodan Fine Chemicals and Exini Diagnostics.

Vorherige Seite2/25Nächste Seite


All videos

Product of the week



LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...


All Events



BioVaria 2015

Job Advert

Sales Manager

celares GmbH is a Berlin based drug delivery company focused on chemical modifications of biological drugs. We offer customized development services for international pharma and biopharma companies and have manufacturing capabilities for key starting materials used for the preparation of pharmaceutical drugs. For the intensification of our own sales activities we are looking for a sales manager. more...

Stock list

All quotes


  • WILEX3.59 EUR5.59%
  • BASILEA118.10 CHF3.14%
  • PAION2.58 EUR2.79%


  • BIOTEST79.20 EUR-19.51%
  • CYTOS1.01 CHF-8.18%
  • FORMYCON28.00 EUR-6.01%


  • CO.DON3.15 EUR22.1%
  • WILEX3.59 EUR21.3%
  • FORMYCON28.00 EUR21.0%


  • CYTOS1.01 CHF-27.9%
  • BIOTEST79.20 EUR-18.1%
  • THERAMETRICS0.07 CHF-12.5%


  • SANTHERA98.85 CHF2460.9%
  • CYTOS1.01 CHF676.9%
  • WILEX3.59 EUR337.8%


  • MOLOGEN5.08 EUR-54.7%
  • THERAMETRICS0.07 CHF-30.0%
  • BIOFRONTERA2.41 EUR-28.1%

No liability assumed, Date: 25.04.2015

Current issue

All issues